| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T23 |
0-10 |
NNS |
denotes |
Highlights |
| T24 |
11-12 |
IN |
denotes |
• |
| T25 |
14-18 |
NNP |
denotes |
IVIG |
| T26 |
18-19 |
-COMMA- |
denotes |
, |
| T27 |
20-28 |
VBN |
denotes |
combined |
| T28 |
29-33 |
IN |
denotes |
with |
| T29 |
34-47 |
NN |
denotes |
moderate-dose |
| T30 |
48-50 |
IN |
denotes |
of |
| T31 |
51-66 |
NNS |
denotes |
corticosteroids |
| T32 |
66-67 |
-COMMA- |
denotes |
, |
| T33 |
68-73 |
MD |
denotes |
might |
| T34 |
74-81 |
VB |
denotes |
improve |
| T35 |
82-89 |
NN |
denotes |
patient |
| T36 |
90-98 |
NNS |
denotes |
outcomes |
| T37 |
100-101 |
PDT |
denotes |
• |
| T38 |
103-106 |
DT |
denotes |
The |
| T39 |
107-110 |
NN |
denotes |
use |
| T40 |
111-113 |
IN |
denotes |
of |
| T41 |
114-129 |
NNS |
denotes |
corticosteroids |
| T42 |
130-135 |
MD |
denotes |
might |
| T43 |
136-146 |
VB |
denotes |
accelerate |
| T44 |
147-155 |
NN |
denotes |
recovery |
| T45 |
156-160 |
IN |
denotes |
from |
| T46 |
161-169 |
NN |
denotes |
COVID-19 |
| T47 |
171-172 |
PDT |
denotes |
• |
| T48 |
174-176 |
DT |
denotes |
No |
| T49 |
177-187 |
VBN |
denotes |
controlled |
| T50 |
188-196 |
JJ |
denotes |
clinical |
| T51 |
197-203 |
NNS |
denotes |
trials |
| T52 |
204-209 |
VBP |
denotes |
exist |
| T53 |
210-212 |
IN |
denotes |
on |
| T54 |
213-216 |
DT |
denotes |
the |
| T55 |
217-220 |
NN |
denotes |
use |
| T56 |
221-223 |
IN |
denotes |
of |
| T57 |
224-239 |
NNS |
denotes |
corticosteroids |
| T58 |
240-243 |
IN |
denotes |
for |
| T59 |
244-252 |
NN |
denotes |
COVID-19 |
| T60 |
254-255 |
LS |
denotes |
• |
| T61 |
257-260 |
NN |
denotes |
IL6 |
| T62 |
261-271 |
VBZ |
denotes |
correlates |
| T63 |
272-276 |
IN |
denotes |
with |
| T64 |
277-285 |
NN |
denotes |
severity |
| T65 |
285-286 |
-COMMA- |
denotes |
, |
| T66 |
287-298 |
NN |
denotes |
criticality |
| T67 |
298-299 |
-COMMA- |
denotes |
, |
| T68 |
300-305 |
JJ |
denotes |
viral |
| T69 |
306-310 |
NN |
denotes |
load |
| T70 |
310-311 |
-COMMA- |
denotes |
, |
| T71 |
312-315 |
CC |
denotes |
and |
| T72 |
316-325 |
NN |
denotes |
prognosis |
| T73 |
326-328 |
IN |
denotes |
of |
| T74 |
329-337 |
NN |
denotes |
COVID-19 |
| T75 |
339-340 |
IN |
denotes |
• |
| T76 |
342-353 |
NNP |
denotes |
Tocilizumab |
| T77 |
353-354 |
-COMMA- |
denotes |
, |
| T78 |
355-357 |
DT |
denotes |
an |
| T79 |
358-366 |
NN |
denotes |
anti-IL6 |
| T80 |
366-367 |
-COMMA- |
denotes |
, |
| T81 |
368-371 |
MD |
denotes |
can |
| T82 |
372-378 |
VB |
denotes |
confer |
| T83 |
379-386 |
NN |
denotes |
benefit |
| T84 |
387-389 |
IN |
denotes |
in |
| T85 |
390-398 |
NNS |
denotes |
patients |
| T86 |
399-403 |
IN |
denotes |
with |
| T87 |
404-412 |
NN |
denotes |
COVID-19 |
| T88 |
413-416 |
CC |
denotes |
and |
| T89 |
417-421 |
JJ |
denotes |
high |
| T90 |
422-425 |
NN |
denotes |
IL6 |
| R20 |
T25 |
T24 |
arg1Of |
IVIG,• |
| R21 |
T25 |
T26 |
arg1Of |
IVIG,"," |
| R22 |
T25 |
T27 |
arg2Of |
IVIG,combined |
| R23 |
T27 |
T28 |
arg1Of |
combined,with |
| R24 |
T29 |
T28 |
arg2Of |
moderate-dose,with |
| R25 |
T29 |
T30 |
arg1Of |
moderate-dose,of |
| R26 |
T31 |
T30 |
arg2Of |
corticosteroids,of |
| R27 |
T34 |
T32 |
arg1Of |
improve,"," |
| R28 |
T25 |
T33 |
arg1Of |
IVIG,might |
| R29 |
T34 |
T33 |
arg2Of |
improve,might |
| R30 |
T25 |
T34 |
arg1Of |
IVIG,improve |
| R31 |
T36 |
T34 |
arg2Of |
outcomes,improve |
| R32 |
T36 |
T35 |
arg1Of |
outcomes,patient |
| R33 |
T39 |
T37 |
arg1Of |
use,• |
| R34 |
T39 |
T38 |
arg1Of |
use,The |
| R35 |
T39 |
T40 |
arg1Of |
use,of |
| R36 |
T41 |
T40 |
arg2Of |
corticosteroids,of |
| R37 |
T39 |
T42 |
arg1Of |
use,might |
| R38 |
T43 |
T42 |
arg2Of |
accelerate,might |
| R39 |
T39 |
T43 |
arg1Of |
use,accelerate |
| R40 |
T44 |
T43 |
arg2Of |
recovery,accelerate |
| R41 |
T44 |
T45 |
arg1Of |
recovery,from |
| R42 |
T46 |
T45 |
arg2Of |
COVID-19,from |
| R43 |
T51 |
T47 |
arg1Of |
trials,• |
| R44 |
T51 |
T48 |
arg1Of |
trials,No |
| R45 |
T51 |
T49 |
arg2Of |
trials,controlled |
| R46 |
T51 |
T50 |
arg1Of |
trials,clinical |
| R47 |
T51 |
T52 |
arg1Of |
trials,exist |
| R48 |
T52 |
T53 |
arg1Of |
exist,on |
| R49 |
T55 |
T53 |
arg2Of |
use,on |
| R50 |
T55 |
T54 |
arg1Of |
use,the |
| R51 |
T55 |
T56 |
arg1Of |
use,of |
| R52 |
T57 |
T56 |
arg2Of |
corticosteroids,of |
| R53 |
T55 |
T58 |
arg1Of |
use,for |
| R54 |
T59 |
T58 |
arg2Of |
COVID-19,for |
| R55 |
T62 |
T60 |
arg1Of |
correlates,• |
| R56 |
T61 |
T62 |
arg1Of |
IL6,correlates |
| R57 |
T62 |
T63 |
arg1Of |
correlates,with |
| R58 |
T71 |
T63 |
arg2Of |
and,with |
| R59 |
T64 |
T65 |
arg1Of |
severity,"," |
| R60 |
T66 |
T65 |
arg2Of |
criticality,"," |
| R61 |
T65 |
T67 |
arg1Of |
",","," |
| R62 |
T69 |
T67 |
arg2Of |
load,"," |
| R63 |
T69 |
T68 |
arg1Of |
load,viral |
| R64 |
T71 |
T70 |
arg1Of |
and,"," |
| R65 |
T67 |
T71 |
arg1Of |
",",and |
| R66 |
T72 |
T71 |
arg2Of |
prognosis,and |
| R67 |
T72 |
T73 |
arg1Of |
prognosis,of |
| R68 |
T74 |
T73 |
arg2Of |
COVID-19,of |
| R69 |
T82 |
T75 |
arg1Of |
confer,• |
| R70 |
T76 |
T77 |
arg1Of |
Tocilizumab,"," |
| R71 |
T79 |
T77 |
arg2Of |
anti-IL6,"," |
| R72 |
T79 |
T78 |
arg1Of |
anti-IL6,an |
| R73 |
T82 |
T80 |
arg1Of |
confer,"," |
| R74 |
T76 |
T81 |
arg1Of |
Tocilizumab,can |
| R75 |
T82 |
T81 |
arg2Of |
confer,can |
| R76 |
T76 |
T82 |
arg1Of |
Tocilizumab,confer |
| R77 |
T83 |
T82 |
arg2Of |
benefit,confer |
| R78 |
T82 |
T84 |
arg1Of |
confer,in |
| R79 |
T85 |
T84 |
arg2Of |
patients,in |
| R80 |
T85 |
T86 |
arg1Of |
patients,with |
| R81 |
T88 |
T86 |
arg2Of |
and,with |
| R82 |
T87 |
T88 |
arg1Of |
COVID-19,and |
| R83 |
T90 |
T88 |
arg2Of |
IL6,and |
| R84 |
T90 |
T89 |
arg1Of |
IL6,high |